KR20150031413A - 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 - Google Patents

항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 Download PDF

Info

Publication number
KR20150031413A
KR20150031413A KR1020147034319A KR20147034319A KR20150031413A KR 20150031413 A KR20150031413 A KR 20150031413A KR 1020147034319 A KR1020147034319 A KR 1020147034319A KR 20147034319 A KR20147034319 A KR 20147034319A KR 20150031413 A KR20150031413 A KR 20150031413A
Authority
KR
South Korea
Prior art keywords
seq
leu
arg
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147034319A
Other languages
English (en)
Korean (ko)
Inventor
김상재
김경희
이규용
고성호
김범준
박현희
허성진
이우진
장화인
하정순
Original Assignee
주식회사 카엘젬백스
김상재
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120079096A external-priority patent/KR20140012385A/ko
Priority claimed from KR1020120089167A external-priority patent/KR20140022699A/ko
Priority claimed from KR1020120089162A external-priority patent/KR20140022698A/ko
Application filed by 주식회사 카엘젬백스, 김상재 filed Critical 주식회사 카엘젬백스
Priority to KR1020207019525A priority Critical patent/KR102302392B1/ko
Publication of KR20150031413A publication Critical patent/KR20150031413A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
KR1020147034319A 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 Ceased KR20150031413A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207019525A KR102302392B1 (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
KR1020120079096 2012-07-20
KR1020120079096A KR20140012385A (ko) 2012-07-20 2012-07-20 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물
KR1020120089167A KR20140022699A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR1020120089162A KR20140022698A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR1020120089162 2012-08-14
KR20120089161 2012-08-14
KR1020120089161 2012-08-14
KR1020120089167 2012-08-14
KR1020120104207 2012-09-19
KR20120104144 2012-09-19
KR20120104207 2012-09-19
KR1020120104144 2012-09-19
PCT/EP2013/055326 WO2014012683A1 (en) 2012-07-20 2013-03-15 Anti-inflammatory peptides and composition comprising the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207019525A Division KR102302392B1 (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Publications (1)

Publication Number Publication Date
KR20150031413A true KR20150031413A (ko) 2015-03-24

Family

ID=47882177

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207019525A Active KR102302392B1 (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR1020147034319A Ceased KR20150031413A (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207019525A Active KR102302392B1 (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Country Status (8)

Country Link
US (6) US20150125438A1 (enExample)
EP (3) EP2875042B1 (enExample)
JP (6) JP6352911B2 (enExample)
KR (2) KR102302392B1 (enExample)
CN (3) CN104470947B (enExample)
ES (2) ES2871899T3 (enExample)
TW (6) TWI836435B (enExample)
WO (1) WO2014012683A1 (enExample)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160131562A (ko) 2015-05-08 2016-11-16 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
WO2016163751A3 (ko) * 2015-04-07 2016-12-01 가톨릭대학교 산학협력단 X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
WO2017179838A1 (ko) * 2016-04-15 2017-10-19 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR20180016410A (ko) * 2015-07-02 2018-02-14 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20180043428A (ko) * 2016-10-19 2018-04-30 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR20180132024A (ko) * 2018-12-03 2018-12-11 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR20200005526A (ko) * 2016-12-22 2020-01-15 유니베르시테 드 몽펠리에 신규한 스테이플화 펩티드 및 이의 용도
KR20200025373A (ko) * 2018-08-30 2020-03-10 충남대학교산학협력단 암 예방 또는 치료용 펩타이드 및 이의 용도
KR20200057592A (ko) * 2018-11-16 2020-05-26 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
KR20200071414A (ko) * 2018-12-11 2020-06-19 대한민국(농촌진흥청장) 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물
KR102266613B1 (ko) * 2020-09-21 2021-06-18 자안바이오 주식회사 항염증 활성을 갖는 신규한 펩티드 및 이의 용도
WO2023214802A1 (ko) * 2022-05-03 2023-11-09 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도
KR20240118630A (ko) * 2023-01-26 2024-08-05 (주) 에빅스젠 신규한 뇌 질환 치료제 및 이의 용도

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320058D0 (en) 1993-09-29 1993-11-17 Gillette Co Savety razors
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN107312759B (zh) 2012-09-19 2025-10-28 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
DK3783011T5 (da) 2013-03-15 2024-08-19 Promega Corp Aktivering af bioluminescens via strukturel komplementering
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
EP3011967B1 (en) 2013-06-21 2020-06-17 Gemvax & Kael Co., Ltd. Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
WO2015005723A1 (ko) * 2013-07-12 2015-01-15 주식회사 카엘젬백스 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
CN106456697B (zh) * 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
KR102232320B1 (ko) 2014-04-30 2021-03-26 주식회사 젬백스앤카엘 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
EP3193906B1 (en) * 2014-09-18 2020-11-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
CA2996951C (en) * 2015-08-28 2024-05-07 The Medical College Of Wisconsin, Inc. Peptide inhibitors of telomerase translocation and therapeutic uses thereof
CA3006044A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
ES2949697T3 (es) * 2016-04-07 2023-10-02 Gemvax & Kael Co Ltd Péptido que tiene efectos de aumento de la actividad telomerasa y de extensión de los telómeros, y composición que contienen el mismo
JP6601848B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
JP6601849B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
US20240174714A1 (en) * 2021-02-08 2024-05-30 Bacoba Ag Treatment of skin disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
EP1293565A3 (en) * 1994-07-07 2004-05-12 Geron Corporation Mammalian telomerase RNA component
PT912558E (pt) * 1996-06-25 2003-11-28 Pfizer Derivados de indazole substituidos e sua utilizacao como inibidores de fosfodiesterase (pde) de tipo iv e de factor de necrose tumoral (tnf)
IL129222A0 (en) * 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
JP2002514928A (ja) * 1997-07-01 2002-05-21 キャンビア バイオシステムス リミティド ライアビリティー カンパニー 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US20030171280A1 (en) * 2001-07-31 2003-09-11 Soderstrom Karl Petter Compositions and methods for modulation of immune responses
JP2005502335A (ja) * 2001-08-08 2005-01-27 インサイト・ゲノミックス・インコーポレイテッド 細胞成長、分化および細胞死関連タンパク質
US8492438B2 (en) * 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2004236708A1 (en) * 2003-05-01 2004-11-18 Musc Foundation For Research Development An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
CN101011571A (zh) * 2006-03-13 2007-08-08 上海交通大学医学院 GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
AU2007306368B2 (en) * 2006-10-12 2012-05-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof
AU2008252628A1 (en) 2007-05-18 2008-11-27 Inhibox Ltd. Bicyclosulfonyl acid (BCSA) compounds and their use as therapeutic agents
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
ES2602453T3 (es) * 2008-06-16 2017-02-21 Mediolanum Farmaceutici S.P.A. Inmunoterapia antitumoral
US8252282B2 (en) * 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
WO2010032322A1 (ja) 2008-09-22 2010-03-25 日清ファルマ株式会社 抗炎症性ペプチド
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN108383894A (zh) * 2010-02-16 2018-08-10 阿尔特公司 多肽及其应用
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
CN115927242A (zh) 2012-05-11 2023-04-07 珍白斯凯尔有限公司 具有抗炎活性的肽及其在制备抗炎组合物中的应用
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN107312759B (zh) 2012-09-19 2025-10-28 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
TWI655204B (zh) 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
CN110064056B (zh) 2012-09-19 2022-10-28 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
CN105535931A (zh) * 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
WO2015005723A1 (ko) 2013-07-12 2015-01-15 주식회사 카엘젬백스 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
US20170112941A1 (en) 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016163751A3 (ko) * 2015-04-07 2016-12-01 가톨릭대학교 산학협력단 X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
US10125367B2 (en) 2015-04-07 2018-11-13 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition for preventing or treating atopic dermatitis comprising X-shape DNA structure as active ingredient
KR20160131562A (ko) 2015-05-08 2016-11-16 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
KR20180016410A (ko) * 2015-07-02 2018-02-14 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
JP2019510077A (ja) * 2016-04-15 2019-04-11 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. 抗炎症活性を有するペプチド及びその用途
WO2017179838A1 (ko) * 2016-04-15 2017-10-19 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
US10925923B2 (en) 2016-04-15 2021-02-23 Caregen Co., Ltd. Peptide having anti-inflammatory activity, and use thereof
US10723777B2 (en) 2016-10-19 2020-07-28 Caregen Co., Ltd. Peptide having anti-obesity and anti-diabetes efficacy and use thereof
KR20180043428A (ko) * 2016-10-19 2018-04-30 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR20200005526A (ko) * 2016-12-22 2020-01-15 유니베르시테 드 몽펠리에 신규한 스테이플화 펩티드 및 이의 용도
KR20200025373A (ko) * 2018-08-30 2020-03-10 충남대학교산학협력단 암 예방 또는 치료용 펩타이드 및 이의 용도
KR20200057592A (ko) * 2018-11-16 2020-05-26 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
KR20180132024A (ko) * 2018-12-03 2018-12-11 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR20200071414A (ko) * 2018-12-11 2020-06-19 대한민국(농촌진흥청장) 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물
KR102266613B1 (ko) * 2020-09-21 2021-06-18 자안바이오 주식회사 항염증 활성을 갖는 신규한 펩티드 및 이의 용도
WO2023214802A1 (ko) * 2022-05-03 2023-11-09 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도
KR20240118630A (ko) * 2023-01-26 2024-08-05 (주) 에빅스젠 신규한 뇌 질환 치료제 및 이의 용도

Also Published As

Publication number Publication date
EP3428182A3 (en) 2019-02-27
ES2693321T3 (es) 2018-12-11
JP2024056904A (ja) 2024-04-23
CN104470947B (zh) 2019-03-08
CN109777791B (zh) 2023-12-01
US20200208127A1 (en) 2020-07-02
US11905536B2 (en) 2024-02-20
EP2875042A1 (en) 2015-05-27
CN104470947A (zh) 2015-03-25
JP7741218B2 (ja) 2025-09-17
TW202417473A (zh) 2024-05-01
US20200140832A1 (en) 2020-05-07
TWI836435B (zh) 2024-03-21
WO2014012683A1 (en) 2014-01-23
EP3896078A1 (en) 2021-10-20
TW202033540A (zh) 2020-09-16
US20170275603A1 (en) 2017-09-28
US20150125438A1 (en) 2015-05-07
JP2017158561A (ja) 2017-09-14
TW201742921A (zh) 2017-12-16
TW202237629A (zh) 2022-10-01
EP2875042B1 (en) 2018-08-08
JP7440581B2 (ja) 2024-02-28
TWI658141B (zh) 2019-05-01
JP6514259B2 (ja) 2019-05-15
TW201938579A (zh) 2019-10-01
ES2871899T3 (es) 2021-11-02
TWI779287B (zh) 2022-10-01
KR20200085927A (ko) 2020-07-15
EP3896078B1 (en) 2025-11-19
EP3428182A2 (en) 2019-01-16
JP6788062B2 (ja) 2020-11-18
JP7128246B2 (ja) 2022-08-30
EP3428182B1 (en) 2021-04-21
JP2022166225A (ja) 2022-11-01
US20210388328A1 (en) 2021-12-16
TW201406957A (zh) 2014-02-16
CN117551631A (zh) 2024-02-13
KR102302392B1 (ko) 2021-09-16
JP2015525768A (ja) 2015-09-07
JP2021011502A (ja) 2021-02-04
CN109777791A (zh) 2019-05-21
JP2019151638A (ja) 2019-09-12
TWI647311B (zh) 2019-01-11
TWI700290B (zh) 2020-08-01
US11098294B2 (en) 2021-08-24
US20240158768A1 (en) 2024-05-16
JP6352911B2 (ja) 2018-07-04

Similar Documents

Publication Publication Date Title
US11905536B2 (en) Anti-inflammatory peptides and composition comprising the same
US12171812B2 (en) Anti-inflammatory peptides and composition comprising the same
KR20160086864A (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141205

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20150312

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180313

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190517

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190517

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200327

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20191118

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180313

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200604

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200427

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20200327

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191118

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190517

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180313

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200706